Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 3/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1820467 | 0.85 | TDP1 (1.00) | LMNATDP1HTTL3MBTL1MAPT | |
| SCHEMBL1822332 | 0.82 | TDP1 (0.74) | LMNATDP1HTTL3MBTL1MAPT | |
| SCHEMBL1823842 | 0.81 | LMNA (0.67) | LMNATDP1HTTL3MBTL1MAPT | |
| SCHEMBL1825643 | 0.79 | TDP1 (0.66) | LMNATDP1HTTL3MBTL1MAPT | |
| SCHEMBL6320995 | 0.77 | TDP1 (0.67) | LMNATDP1HTTL3MBTL1MAPT | |
| SCHEMBL11073261 | 0.75 | TDP1 (0.63) | LMNATDP1HTTL3MBTL1MAPT | |
| SCHEMBL4265139 | 0.74 | LMNA (0.59) | LMNATDP1HTTL3MBTL1MAPT | |
| SCHEMBL11065466 | 0.72 | TDP1 (0.60) | LMNATDP1HTTL3MBTL1MAPT | |
| SCHEMBL4549451 | 0.70 | MAPT (0.58) | LMNATDP1HTTL3MBTL1MAPT | |
| SCHEMBL10848495 | 0.70 | LMNA (0.54) | LMNATDP1L3MBTL1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100158863-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158863-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | SLC28A1, TPMT, ACE | LMNA 4439/4885TDP1 377/4885HTT 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.